SEC Company Response from Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — May 6, 2020
Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: May 6, 2020 · CIK: 0000876343 · Accession: 0001493152-20-007837
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237975
Letter
VIA EDGAR Division of Corporation Finance Attn: Abby Adams Registration Statement on Form S-3 File No. 333-237975
RE: Lineage Cell Therapeutics, Inc.
Dear Ms. Adams:
Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-237975) be accelerated and that it be declared effective on May 8, 2020 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
Sincerely,
/s/
Brandi L. Roberts
Show Raw Text
CORRESP
1
filename1.htm
VIA
EDGAR
May
6, 2020
U.S.
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn:
Abby Adams
RE:
Lineage
Cell Therapeutics, Inc.
Registration
Statement on Form S-3
File
No. 333-237975
Dear
Ms. Adams:
Lineage
Cell Therapeutics, Inc., a California corporation (the “Company”), respectfully requests pursuant to
Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on
Form S-3 (File No. 333-237975) be accelerated and that it be declared effective on May 8, 2020 at 4:00 p.m. Eastern Time, or as
soon as practicable thereafter.
Sincerely,
/s/
Brandi L. Roberts
Chief
Financial Officer
cc:
Chase
Leavitt, General Counsel, Lineage Cell Therapeutics, Inc.
Steven
M. Przesmicki, Esq., Cooley LLP